The technologyneeded to geneticallyengineer antibodiesis evolving rapidly and the potential utility of these novel reagents is being explored with vigor. The process includes cloningof the antibodygenes, their in vitromanipulationand mutagenesis, expression in a suitable host/vectorsystem, and, for commercial production,scale-up, purification,and productevaluation.At each step, significantadvances have been achieved recently.Forexample:at first,antibodygenes were cloned from genomic librariesby using adjacent DNA probes;techniquesfor rapidsequencingby pnmerextension of total mRNA allowed more specificscreeningwith synthesized oligomers;finally,antibodygenes can now be created de novo by chemical synthesis. Moreover, such synthesis allows total control over the antibody sequence so that molecules of any configuration can be produced. New reagents created in this way includemunne antibodieswhose constantregionsand variable-regionframeworkshave been replacedwith human sequence to enhance immunocompatibility with patients, to switch immunoglobulin class, or both. [3] [4] [5] , and some of these are clinically relevant (e.g.,
Genetic EngineerIng of AntIbodies
The process by which genetically engineered antibody variants can be created has been reviewed extensively elsewhere (e.g., 9, 10). The 
For each antibody of interest, engineering
begins by cloning the variable regions, which dictates antigen specificity. DNA is isolated from hybridoma cells and cloned, usually in Aphage vectors. The phage library is screened by hybridization with a radioactively labeled probe. Because the genomic rearrangement that results in production of functional immunoglobulin genes leaves common sequences between the variable (V) and constant (C) regions, any functional heavy-chain gene can be isolated with a single ("universal") probe.' The same is true for the light chain. These clones can be verified with synthesized oligomere as described below.
Once the desired V regions have been isolated, they must be cloned into a vector appropriate for expression. If immunocompatibility is an objective, it is desirable that the expression vector contain a human C region; given that most available hybridomas are murine, the V region is usually from mouse. Moreover, panels of expression vectors now exist, each containing a different human C region. Thus, the isotype of the antibody can be chosen at will.
Expression vectors have been designed for use in bacteria, yeast, or mammalian cells (2, 11, 12). The most common hosts are murine myeloma cells, which, through mutation, have lost the ability to make endogenous antibody. Vectors for myeloma cells usually contain heavy(H)-and light(L)-chain genes individually, and these are cointroduced into the host (6, 7) . In addition to the murine V and human C regions, the vectors contain a bacterial origin of replication and drug-selectable markers to identify which cells have taken up and expressed the vectors. The immunoglobulin genes are usually controlled by their own promoters and enhancers. These constructions may contain 
Purificationof Murine V/Human C ChimericAntibodies
Once a cell line secreting the engineered antibody has been identified, it must be scaled-up for production. This can be done in tissue culture or by growing the cells in mice and collecting antibody from ascites fluid. Various purification schemes have been reported (e.g., 15), some of which utilize the binding activity of the antibody. My colleagues and I have used methods that rely on properties of the human C regions that distinguish chimeric from contaminating antibodies. In the case of tissue culture media, the major contaminant is bovine antibody found in serum. As shown in Figure 1 IgG (16). Both these methods yield chimeric antibody of sufficient purity for subsequent functional analysis. Moreover, these methods can be applied to any murine V/human C chimeric antibody without regard to its antigen specificity.
Characterization of Chimeric Antibodies
As described above, a virtually limitless array of new antibody variants can be produced by genetic engineering. The utility of each reagent for immunotherapy must ultimately be determined in clinical trials. Because such trials are laborious and costly, it is critical that novel variants be screened by various in vitro assays or in animal studies.
The nature of such analysis is dependent upon the particular antibody in question. To illustrate, I refer to a murine V/human C chimera of the murine antibody B6.2 (6), which has specificity for human breast, colon, and lung carcinomas (17 respect to a variety of biochemical, biological, and immunologic characteristics (6, 16) showed that, for example, the murine and chimeric antibodies bound to the same panel of cell types (Figure 3) . Most important, competition studies carried out in the cell sorter or with in-vivo-labeled antibody demonstrated that the chimeric and murine molecules competed for binding to antigen to an approximately equal extent (Figure 4) . This important result implied that exchange of the human and murine C regions had little or no effect on the ability of the antibody to bind antigen. In a further test, chimeric
B6.2 was used successfully to image a human tumor implanted in a mouse (Figure 5).
Murine V/human C chimeric antibodies of many specificities now have been produced in several laboratories. In Their utility in immunotherapy is being tested in various clinical trials, the results of which should be available over the next few years. It is hoped that, because of their presumed greater immunocompatability in patients, they will outperform the murine antibodies from which they are derived. Meanwhile, new kinds of antibody variants are being produced and tested (see below).
Increasing the Expression Level of Engineered Antibodies
A major issue in the widespread clinical application of genetically engineered antibodies will be the ability to produce them in large amounts. This is particularly important because many immunotherapeutic regimens involve repeated administration of relatively large doses of antibodies. Unfortunately, engineered antibodies expressed by transfection into eukaryotic hosts, e.g., myeloma cells, often are not produced efficiently. Most "transfectomas" produce 2-10 pg/1O6 cells per day; this is only 1-10% of the production level of the best murine hybridomas.
The probable reason is that the transfected genes integrate into the host chromosomes at random and, therefore, at loci that are not necessarily optimal for expression. Although antibody genes have been expressed in yeast and bacteria, there are problems in chain association, secretion, glycation, and biological activity.
We have attempted to increase the expression of transfected antibody genes by linking them to genes that can be amplified by a slow increase in the concentrations of various drugs (18). As the number of copies of the amplifiable gene increases in response to the drug, the linked antibody gene(s) is also amplified in copy number. This amplification results in an increase in gene expression and thus increased secretion of antibody.
A commonly utilized gene-drug combination is the gene coding for dihydrofolate reductase, which is amplified by the drug methotrexate. We have adapted this combination for use in myeloma cells; a representative vector is shown in Figure  6 . Using this vector, we have achieved a large increase in the expression of transfected immunoglobulin genes (18). Moreover, similar ampliflable vectors are now being used to express nonimmunoglobulin genes in myeloma cells (19, and M. Hendricks, Integrated Genetics, unpublished). 
The Use of DNA Synthesis In AntIbody EngIneering
The chemical synthesis of DNA of desired nucleotide sequence is an important new technology in molecular biology. The process has now been automated, and fragments about 100 nucleotides long can be made without great difficulty. We have been applying this technique to antibody engineering in a variety of ways.
The process of cloning desired V regions is laborious because genomic libraries must be constructed and the tiny minority (perhaps one in 106) of target clones must be purified from the background. Moreover, a serious problem is that aberrantly rearranged, and hence nonfunctional, V regions are often obtained from the screen (20). These problems can be circumvented by synthesizing the desired V regions de novo rather than cloning them.
Obviously, the DNA sequence of the region must be determined before synthesis. Because mRNA that specifies immunoglobulin is so prevalent in hybridoma cells, this can be accomplished directly (21). Poly A mRNA is isolated from the hybridoma and hybridized with a short "universal" DNA primer synthesized with the knowledge of the sequence of the common C region. The duplex is then extended by using reverse transcriptase, and the product is sequenced. This sequence can be used to make specific probes to screen libraries.
The more innovative approach is to synthesize the entire V region. Although the sequence is too long (400-500 nucleotides) to synthesize in one piece, several alternative methods are available to assemble the synthesized fragments. One technique is to synthesize pairs of opposite strands with restriction sites at their ends and short overlaps. The overlaps are annealed, then the structure is filled in with DNA polymerase. The resulting double-stranded fragments are then ligated through the restriction sites at their ends to form the finished structure. Depending on the length, intermediate cloning may be required to generate sufficient material for the next step. Care must be taken that the engineered restriction sites do not interfere with either the desired amino acid sequence or with physiologic codon usage. The number of known restriction sites is so large, however, that this is rarely a problem.
The advantage of polymerase is that it reduces the amount of DNA synthesis required.
The disadvantage is that the error rate is relatively high. Because even a one-base error can render the construct nonfunctional, each piece must be sequenced after synthesis and after each cloning step.
A second method involves synthesis of both complementary strands in their entirety. A 10-to 15-nucleotide "overhang" allows ligation of serial double-stranded fragments. Surprisingly, one simply mixes a relatively large number of single-stranded, overlapping fragments. This complex reaction results simultaneously in opposite-strand hybridization and overlapping pair ligation to form the completed structure in a single step. The synthesized V region is then cloned, sequenced (for verification), and inserted into an appropriate expression vector. As described above, one advantage of total V region synthesis is ease and speed. A second advantage is avoidance of cloning aberrant V regions. More importantly, however, this method gives absolute control over the structure of the resulting gene. Thus, any variant can be created easily. Further, mixing of nucleotides at nucleotide addition steps during the gene synthesis generates multiple amino acids at particular positions. This new form of in vitro mutagenesis is extremely powerful.
Replacement of Compiementarity-Determinlng Regions
Any antibody variant can be made by using the technique of total gene synthesis. Technical limitations include possible problems with message or protein stability, chain association, glycation, or secretion. The major limitations, however, are the creative imagination, the knowledge of antibody structure/function needed to design improved antibodies, and the resources necessary to test them.
A major goal of antibody engineering is to make immunocompatible therapeutic agents. I have described chimeric antibodies containing human C regions. These reagents, however, are still capable of eliciting host immune response against portions of the rodent V regions (22) . As an example of the use of total gene synthesis, I now describe a new antibody variant designed to reduce further, or eliminate, host response to therapeutic antibodies.
It has been known for some time that most antigen specificity resides in defined portions of the V regions called "hypervariable" or "complementarity-determining" regions (CDRs) (23). Spatially, the CDRs are looped away from the V region framework, which consists of a pleated sheet (24). These CDR loops form the antigen-combining sites. Comparison of V region sequence among immunoglobulins from a wide variety of sources shows that sequence variation is far greater in the CDRs than elsewhere in the V region (25) . Consequently, it should be possible to transplant the CDRS from a rodent antibody into a human framework (3,10) and to maintain the antigen specificity of the rodent parent antibody while eliminating host response to the V region framework. Further, because the CDRs are so variable, even within a species, they are unlikely to elicit an immune response. Thus, host immune response should be reduced greatly, or eliminated, by CDR replacement.
The three H-chain and three L-chain CDRS are interspersed with framework sequence. Thus, total gene synthesis represents the most practical way to make CDR-replaced variants. In our hands, the process is carried out as shown in Figure 7 . Poly A mRNA is isolated from the target rodent hybridoma and sequenced as described previously. A computer search is made to identify a closely related pair of human H and L chains. Alternatively, one can utilize the most related H and L chains and assume that they will later be capable of association. The next step Figure 7 is that unique restriction sites have been engineered at the CDR/framework borders. In the future, new antibody specificities will be generated by insertion of synthesized CDRS at these sites rather than by synthesis and assembly of the entire V regions. This will result in a significant saving of effort.
One CDR-replaced antibody has been described by Riechmann et al. (10) , and others are being evaluated in our laboratory and elsewhere. Many other engineered antibody variants are also being produced and studied. At the least, this work will result in a greater understanding of immunoglobulin structure and function. New molecules will be produced that can be applied successfully for immunotherapy.
